David G Parkes Selected Research

David G Parkes Research Topics

Disease

17	Body Weight (Weight, Body) 01/2021 - 04/2005
16	Weight Loss (Weight Reduction) 07/2015 - 12/2007
13	Obesity 11/2021 - 12/2007
9	Type 2 Diabetes Mellitus (MODY) 07/2015 - 02/2004
8	Insulin Resistance 01/2021 - 04/2005
4	Hyperglycemia 11/2021 - 08/2009
4	Metabolic Diseases (Metabolic Disease) 01/2021 - 05/2012
3	Hypertension (High Blood Pressure) 01/2018 - 08/2009
2	Inflammation (Inflammations) 11/2021 - 12/2010
2	Glucose Intolerance 01/2021 - 01/2018
1	Albuminuria 01/2020
1	Hypoglycemia (Reactive Hypoglycemia) 02/2013
1	Chronic Disease (Chronic Diseases) 02/2013
1	Non-alcoholic Fatty Liver Disease 04/2012
1	Fibrosis (Cirrhosis) 04/2012
1	Hepatomegaly 04/2012
1	Necrosis 12/2010
1	Pancreatitis 12/2010
1	Weight Gain 12/2010
1	Myocardial Infarction 11/2010
1	Heart Failure 11/2010
1	Cardiovascular Diseases (Cardiovascular Disease) 11/2010
1	AIDS-Related Complex (ARC) 01/2010
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 08/2009
1	Hypertriglyceridemia 08/2009
1	Overweight 05/2008
1	Disease Progression 02/2004

Drug/Important Bio-Agent (IBA)

13	Exenatide (Byetta)FDA Link 04/2014 - 02/2004
11	Islet Amyloid PolypeptideIBA 07/2015 - 12/2007
9	Glucose (Dextrose)FDA LinkGeneric 11/2021 - 04/2005
8	LeptinIBA 01/2013 - 05/2008
6	Insulin (Novolin)FDA Link 01/2021 - 04/2005
6	Peptides (Polypeptides)IBA 07/2015 - 05/2008
5	IncretinsIBA 08/2009 - 04/2005
4	LipidsIBA 01/2021 - 04/2005
4	Glucagon-Like Peptide 1 (GLP 1)IBA 12/2010 - 05/2006
3	AC3174IBA 04/2012 - 08/2010
2	Messenger RNA (mRNA)IBA 11/2021 - 01/2010
2	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2020 - 01/2018
2	Glucagon-Like Peptide-1 ReceptorIBA 01/2020 - 04/2012
2	Triglycerides (Triacylglycerol)IBA 01/2018 - 04/2012
2	pramlintide (Symlin)FDA Link 07/2015 - 05/2008
2	Lipase (Acid Lipase)FDA Link 04/2014 - 12/2010
2	Amylases FDA Link 04/2014 - 12/2010
2	Alanine Transaminase (SGPT)IBA 04/2014 - 04/2012
2	Cholecystokinin (Pancreozymin)IBA 01/2013 - 05/2010
1	Hormones (Hormone)IBA 01/2021
1	gastric inhibitory polypeptide receptorIBA 01/2021
1	Liraglutide FDA Link 01/2021
1	Blood Glucose (Blood Sugar)IBA 01/2021
1	NADPH Oxidase 4IBA 01/2020
1	Oxidants (Oxidizing Agents)IBA 01/2020
1	olmesartanIBA 01/2018
1	Amylin Receptor AgonistsIBA 07/2015
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 04/2014
1	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 04/2014
1	Glucagon (Glukagon)FDA Link 02/2013
1	Dopamine (Intropin)FDA LinkGeneric 01/2013
1	Opioid Analgesics (Opioids)IBA 01/2013
1	Naltrexone (ReVia)FDA LinkGeneric 01/2013
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2013
1	Phentermine (Adipex-P)FDA LinkGeneric 01/2013
1	Bupropion (Wellbutrin)FDA LinkGeneric 01/2013
1	sibutramine (Meridia)FDA Link 01/2013
1	MelanocortinsIBA 01/2013
1	davalintideIBA 01/2013
1	lardIBA 04/2012
1	Estradiol (Delestrogen)FDA LinkGeneric 12/2010
1	CytokinesIBA 12/2010
1	Taurocholic Acid (Sodium Taurocholate)IBA 12/2010
1	CeruletideIBA 12/2010
1	salicylhydroxamic acid (SHAM)IBA 12/2010
1	Glucagon-Like Peptide-1 Receptor AgonistsIBA 11/2010
1	Anti-Obesity Agents (Antiobesity Drugs)IBA 09/2010
1	SaltsIBA 08/2010
1	Captopril (Capoten)FDA LinkGeneric 08/2010
1	antineoplaston A10 (A 10)IBA 01/2010
1	Leptin ReceptorsIBA 01/2010
1	GlucocorticoidsIBA 08/2009
1	CorticosteroneIBA 08/2009
1	Antihypertensive Agents (Antihypertensives)IBA 08/2009
1	CarbohydratesIBA 11/2008
1	AcidsIBA 05/2008
1	Peptide Hormones (Polypeptide Hormones)IBA 12/2007
1	peptide YY (3-36)IBA 12/2007
1	Amino Acids FDA Link 05/2006
1	Hemoglobin AIBA 04/2005

Therapy/Procedure

6	Therapeutics 01/2021 - 12/2007
2	Injections 02/2013 - 05/2008
2	Glycemic Control 02/2013 - 02/2004
1	Duration of Therapy 01/2018
1	Ovariectomy (Oophorectomy) 12/2010
1	Ligation 11/2010
1	Drug Therapy (Chemotherapy) 05/2008
1	Subcutaneous Infusions 12/2007